Although there’s a mysterious quiet at Glaxo recently, the herpes vaccine Simplirix (formerly Herpevac) is finishing up Phase III trials. It won’t be of any use to anyone who already has herpes, but it’s the first real attempt to bring a vaccine to market. Current data suggests that the vaccine is around 75% effective at preventing infection and/or visible sores in women who don’t already carry either herpes type.

For some slightly dated information on this vaccine, take a look here.